Selected Posters and Abstracts
Tenofovir (Viread)
•[P61] Virologic suppression is maintained in antiretroviral experienced adults who change from tenofovir and lamivudine to Truvada, a once daily fixed-dose combination tablet of tenofovir and emtricitabine
Amy E Colson and others.
•[P156] Renal function in patients taking tenofovir and non-tenofovir based antiretroviral regimens
M M Rosenvinge and others.
•[P219] Selection of L214F after tenofovir failure: role in resistance
Carolina Gutierrez and others.
•[PL3.4] HIV-1 subtype C viruses rapidly develop K65R resistance against ddI and tenofovir
Mark A Wainberg and others.
•[P80] The safety and the effectiveness of antiretroviral therapy containing atazanavir/ritonavir (ATV/r) with or without tenofovir (TDF)
Ana Guelar and others.
•[P136] Changes in body weight, anthropometric measurements and lipid levels in tenofovir containing antiretroviral therapy
J Wembri and others.
•[P155] Changes in creatinine clearance over time in a patient cohort on tenofovir as part of combined antiretroviral therapy
Imali Fernando and others.
•[P14] Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in the treatment of antiretroviral naive HIV-1 infected patients
John Borrill and others.
•[P140] Mitochondrial effects of didanosine dosage reduction when administered together with tenofovir
G Garrabou and others.
•[P49] Clinically stable treatment-experienced adults receiving tenofovir and didanosine
Andrea Beltrame and others.
•[P27] Response to mono-class nucleoside regimen of tenofovir DF + trizivir in antiretroviral-experienced patients: 48 week results and predictors of response
B Dauer and others.
•[P34] Tenofovir plus didanosine backbone in HIV-patients failing HAART
M Bongiovanni and others.
•[P154] Nephrotoxicity in HIV patients receiving combination antiretroviral therapy including tenofovir: results from the SCOLTA Project
Giordano Madeddu and others.
•[PL13.2] Predictors of creatinine (Cr) increase and drug discontinuation in patients receiving tenofovir DF (TDF)
M Harris and others.
•[PL2.5] Saquinavir/r (SQV/r) BID vs lopinavir/r (LPV/r) BID plus emtricitabine/tenofovir (FTC/TDF) QD in ARV-naive HIV-1 infected patients: GEMINI Study
J Slim and others.
•[P219A] Outcomes of antiretroviral regimens containing Abacavir (ABC) with Tenofovir (TDF) in treatment-experienced patients: predictors of response and drug resistance evolution in failing patients
S Di Giambenedetto and others.
•[P151] Renal safety profile of tenofovir plus didanosine containing regimens. Results from the DIDITEN cohort
Félix Gutierrez and others.
•[P152] The safety and efficacy of tenofovir DF (TDF) in combination with lamivudine (3TC) and efavirenz (EFV) through 5 years in antiretroviral-naive patients 
I Cassetti and others.
•[P157] Renal safety profile of Tenofovir DF (TDF)-containing compared to non-TDF-containing regimens in antiretroviral-naive patients with mild renal impairment or hypertension and/or diabetes mellitus
S Staszewski and others.
•[P153] Tenofovir (TDF)- versus non-TDF-containing ART: renal safety in daily practice
E Wolf and others.
•[P150] Comparison of efficacy and toxicity profile of abacavir (ABA) and tenofovir (TDF) containing regimens
C Smith and others.
•[P120] Switch from stavudine (d4T) to tenofovir DF (TDF) in combination with lamivudine (3TC) and efavirenz (EFV) resulted in continued virologic suppression and improvement in lipoatrophy through 2 years in HIV-infected patients
J VR Madruga and others.
•[P53] Impact of switching virologically suppressed, HIV-infected patients from fixed-dose zidovudine/lamivudine (CBV) to fixed-dose tenofovir DF/emtricitabine (TVD)
Edwin DeJesus and others.
•[P48] CD4+ T-cell evolution after tenofovir/didanosine backbone (TDF/DDI) in presence of undetectable HIV-RNA
C Torti and others.
•[P50] Study of changes in CD4 cells count after switching tenofovir to abacavir or TDF and didanosine to ABC+lamivudine in patients with a ddI+TDF containing regimen and viral suppression (Europa study): preliminary analysis
E Pedrol  and others.
•[P6] Efficacy and safety of Tenofovir DF (TDF), Emtricitabine (FTC) and Efavirenz (EFV) compared to fixed dose Zidovudine/lamivudine (CBV) and EFV through 96 weeks in antiretroviral treatment-naive patients
A Pozniak and others.
•[P1] Once-daily boosted fosamprenavir (FPV/r) or atazanavir (ATV/r) with tenofovir (TDF)/emtricitabine (FTC) in antiretroviral naive HIV-1 infected patients: 24-week results from COL103952 (ALERT)
K Smith and others.
•[P274] Steady-state pharmacokinetics (PK) of tenofovir (TDF) and fosamprenavir (FPV) after once daily (QD) TDF with unboosted or ritonavir (r)-boosted twice daily (BID) FPV in healthy volunteers
A Luber and others.
•[P396] Anti-platelet activating factor (PAF) effects of HAART: a new insight in the drug therapy of HIV infection?
A B Tsoupras and others.
  

 

<— Conference Main Page

Conference
Main Page


FDA-Approved
HIV and AIDS Treatments

Protease Inhibitors
Agenerase
Aptivus
Crixivan
Fortovase
Invirase
Kaletra
Lexiva
Norvir
Prezista
Reyataz
Viracept

Nucleoside / Nucleotide Reverse Transcriptase Inhibitors
Combivir
Epivir
Emtriva
Epzicom
Hivid
Retrovir
Trizivir
Truvada  
Videx
Viread
Zerit
Ziagen

non Nucleoside Reverse Transcriptase Inhibitors
Rescriptor
Sustiva
Viramune

Entry Inhibitors
 Fuzeon

Fixed-dose Combinations
Atripla
Combivir
Trizivir
Truvada